Literature DB >> 22179528

The role of APP proteolytic processing in lipid metabolism.

Marcus O W Grimm1, Tatjana L Rothhaar, Tobias Hartmann.   

Abstract

Amyloid plaques in brains are one of the major pathological hallmarks of Alzheimer's disease (AD). These plaques are mainly formed by aggregated Aβ, generated by proteolytic cleavage of the amyloid precursor protein (APP). Therefore, APP processing and Aβ production have been one of the central scopes in AD research in the past. Now, accumulating evidence suggests that besides its pathological impact, APP and its cleavage products also contribute to physiological functions. Proteolytic cleavage of APP is tightly regulated, and several lipids such as cholesterol and sphingolipids have been shown to influence APP processing and Aβ generation. In turn, Aβ as well as other APP cleavage products plays an essential role in regulating lipid homeostasis arguing for complex regulatory cycles in which lipids control APP processing and vice versa. This balanced regulation is disrupted under pathological conditions such as in AD. This article will review the physiological function of APP and its proteolytic products, especially Aβ and AICD, in regulating lipid homeostasis and which lipid species modulate APP processing. Furthermore, we summarize the alterations in lipid metabolism observed in AD patients and AD mouse models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22179528     DOI: 10.1007/s00221-011-2975-6

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  125 in total

1.  Regional distribution of brain gangliosides in Alzheimer's disease.

Authors:  S Kalanj; I Kracun; H Rosner; C Cosović
Journal:  Neurol Croat       Date:  1991

2.  Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis.

Authors:  H Satoi; H Tomimoto; R Ohtani; T Kitano; T Kondo; M Watanabe; N Oka; I Akiguchi; S Furuya; Y Hirabayashi; T Okazaki
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Regional membrane phospholipid alterations in Alzheimer's disease.

Authors:  M R Prasad; M A Lovell; M Yatin; H Dhillon; W R Markesbery
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

4.  The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis.

Authors:  Toshinori Ozaki; Yuanyuan Li; Hironobu Kikuchi; Taisuke Tomita; Takeshi Iwatsubo; Akira Nakagawara
Journal:  Biochem Biophys Res Commun       Date:  2006-10-09       Impact factor: 3.575

5.  From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry.

Authors:  Marcus O W Grimm; Sven Grösgen; Matthias Riemenschneider; Heikki Tanila; Heike S Grimm; Tobias Hartmann
Journal:  J Chromatogr A       Date:  2011-07-30       Impact factor: 4.759

6.  Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains.

Authors:  Marie Molander-Melin; Kaj Blennow; Nenad Bogdanovic; Birgitta Dellheden; Jan-Eric Månsson; Pam Fredman
Journal:  J Neurochem       Date:  2005-01       Impact factor: 5.372

7.  Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms.

Authors:  Marcus O W Grimm; Johanna Kuchenbecker; Sven Grösgen; Verena K Burg; Benjamin Hundsdörfer; Tatjana L Rothhaar; Petra Friess; Martijn C de Wilde; Laus M Broersen; Botond Penke; Mária Péter; László Vígh; Heike S Grimm; Tobias Hartmann
Journal:  J Biol Chem       Date:  2011-02-15       Impact factor: 5.157

8.  Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD).

Authors:  Thorsten Müller; Caoimhin G Concannon; Manus W Ward; Ciara M Walsh; Anca L Tirniceriu; Florian Tribl; Donat Kögel; Jochen H M Prehn; Rupert Egensperger
Journal:  Mol Biol Cell       Date:  2006-11-08       Impact factor: 4.138

9.  Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind).

Authors:  Miguel A López-Toledano; Michael L Shelanski
Journal:  J Alzheimers Dis       Date:  2007-11       Impact factor: 4.472

10.  Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?

Authors:  Pavel Katsel; Celeste Li; Vahram Haroutunian
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

View more
  26 in total

1.  The physiological functions of the β-amyloid precursor protein APP.

Authors:  Ulrike C Müller; Claus U Pietrzik; Thomas Deller
Journal:  Exp Brain Res       Date:  2012-04       Impact factor: 1.972

Review 2.  Protein prenylation and synaptic plasticity: implications for Alzheimer's disease.

Authors:  David A Hottman; Ling Li
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

Review 3.  Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease.

Authors:  M Isabel G Lopez Sanchez; Peter van Wijngaarden; Ian A Trounce
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

4.  Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Expert Opin Emerg Drugs       Date:  2012-03-23       Impact factor: 4.191

Review 5.  Cholesterol as a co-solvent and a ligand for membrane proteins.

Authors:  Yuanli Song; Anne K Kenworthy; Charles R Sanders
Journal:  Protein Sci       Date:  2013-11-18       Impact factor: 6.725

Review 6.  The future of blood-based biomarkers for Alzheimer's disease.

Authors:  Kim Henriksen; Sid E O'Bryant; Harald Hampel; John Q Trojanowski; Thomas J Montine; Andreas Jeromin; Kaj Blennow; Anders Lönneborg; Tony Wyss-Coray; Holly Soares; Chantal Bazenet; Magnus Sjögren; William Hu; Simon Lovestone; Morten A Karsdal; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

7.  Dual effect of docosahexaenoic acid (attenuation or amplification) on C22:0-, C24:0-, and C26:0-induced mitochondrial dysfunctions and oxidative stress on human neuronal SK-N-BE cells.

Authors:  A Zarrouk; T Nury; J M Riedinger; O Rouaud; M Hammami; G Lizard
Journal:  J Nutr Health Aging       Date:  2015-02       Impact factor: 4.075

8.  Competition between homodimerization and cholesterol binding to the C99 domain of the amyloid precursor protein.

Authors:  Yuanli Song; Eric J Hustedt; Suzanne Brandon; Charles R Sanders
Journal:  Biochemistry       Date:  2013-07-18       Impact factor: 3.162

Review 9.  Cholesterol in brain disease: sometimes determinant and frequently implicated.

Authors:  Mauricio G Martín; Frank Pfrieger; Carlos G Dotti
Journal:  EMBO Rep       Date:  2014-09-15       Impact factor: 8.807

10.  FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons.

Authors:  Nobumasa Takasugi; Tomoki Sasaki; Ihori Ebinuma; Satoko Osawa; Hayato Isshiki; Koji Takeo; Taisuke Tomita; Takeshi Iwatsubo
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.